Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A40AEG0
Fri, 25.04.2025       Pentixapharm Holding AG

Berlin, Germany, April 25, 2025 – Pentixapharm, a clinical-stage biopharmaceutical company focused on radiopharmaceuticals, will present new pre-clinical data on its novel antibody GT-008 at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30 in Chicago. The presentation highlights GT-008’s unique glyca [ … ]
Thu, 24.04.2025       Pentixapharm Holding AG

Berlin, Germany, April 24, 2025 – Pentixapharm, a clinical-stage biopharmaceutical company, today announced the signing of a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTh [ … ]
Tue, 15.04.2025       Pentixapharm Holding AG

Berlin, April 15, 2025 – The Management Board and Supervisory Board of Pentixapharm Holding AG today announced the following key resolutions: The Group closed the 2024 financial year with a net loss of EUR 12.8 million, as reflected in the newly published annual financial statements. Based on current planning, the Company expects a net loss of ap [ … ]
Mon, 03.03.2025       Pentixapharm Holding AG

Berlin, Germany, March 3, 2025 - Several previously announced personnel changes in the governing bodies of the Pentixapharm Group have taken effect as of March 1, 2025. The Management Board of the parent company Pentixapharm Holding AG is now identical in composition to the Management Board of the wholly owned operational subsidiary Pentixapharm AG [ … ]
Thu, 13.02.2025       Pentixapharm Holding AG

Berlin, Germany, February 13, 2025 – Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm’s Lu177-PentixaTher compound will be shown at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO-GU 2025) in San Francisco, CA. The presentation features a case study of a [ … ]
Fri, 24.01.2025       Pentixapharm Holding AG

Berlin, January 24, 2025 - According to initial preliminary evaluations, Pentixapharm Holding AG will close the 2024 financial year with a loss of around EUR 14 million. In addition to the operating loss of EUR 7 million, the total also includes non-cash write-downs for intangible assets. They result from the termination of development projects at  [ … ]
Tue, 07.01.2025       Pentixapharm Holding AG

Berlin, January 7th, 2025 – Pentixapharm AG, a developer of innovative radiopharmaceuticals, receives 6.77 million Euro for intangible assets formerly developed by Glycotope from undisclosed Asian pharma and biotech companies. The transaction, which will be effective still in 2024, involves rights that had been transferred to Pentixapharm as part o [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Saturday, 26.04.2025, Calendar Week 17, 116th day of the year, 249 days remaining until EoY.